United Therapeutics Corporation ($UTHR) Stock Forecast: Up 2.1% Today

What is United Therapeutics Corporation?

United Therapeutics (UTHR) is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. The overall market sentiment for UTHR today was bullish.

Why is United Therapeutics Corporation going up?

UTHR stock is up 2.1% on Apr 30, 2025 14:30

• UTHR's strong bullish movement today can be attributed to the company's impressive Q1 earnings and revenue results, surpassing analyst estimates by 5.41% and 9.39% respectively. This positive financial performance likely instilled confidence in investors, driving up the stock price.
• Despite the overall bullish market movement, it's interesting to note that there were downgrades from a top analyst, which could have initially caused some uncertainty. However, the market seemed to focus more on the robust earnings report, overshadowing the analyst's revised outlook.
• The market's reaction indicates that investors placed more weight on UTHR's solid financial fundamentals rather than the analyst's downgrade, showcasing the significance of strong earnings in influencing stock price movements.

UTHR Price Chart

UTHR Technical Analysis

UTHR News

United Therapeutics ( UTHR ) Q1 Earnings and Revenues Top Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of 5.41% and 9.39%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2458612/united-therapeutics-uthr-q1-earnings-and-revenues-top-estimates

This United Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday - ASGN ( NYSE:ASGN ) , Philip Morris Intl ( NYSE:PM )

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

https://www.benzinga.com/analyst-ratings/downgrades/25/04/45006460/this-united-therapeutics-analyst-is-no-longer-bullish-here-are-top-4-downgrades-for-fr

Trending Today

Moderna Inc. ($MRNA) Stock Forecast: Down 5.1% Today

CVS Health Corporation ($CVS) Stock Forecast: Up 6.9% Today

AGCO Corporation ($AGCO) Stock Forecast: Up 11.8% Today

Affirm Holdings Inc. ($AFRM) Stock Forecast: Up 5.6% Today

Altice USA, Inc. ($ATUS) Stock Forecast: Up 5.1% Today

Sirius XM Holdings Inc. ($SIRI) Stock Forecast: Down 2.3% Today

Novo Nordisk A/S ($NVO) Stock Forecast: Down 1.3% Today

WESCO International, Inc. ($WCC) Stock Forecast: Down 3.7% Today

Marathon Digital Holdings Inc. ($MARA) Stock Forecast: Up 8.3% Today

PTC Inc. ($PTC) Stock Forecast: Up 5.0% Today

United Therapeutics Corporation Price History

28.07.2024 - UTHR Stock was up 5.0%

• The price target for UTHR was raised from $400 to $575, suggesting optimism and growth potential.
• The CEO selling over $2.5 million in company stock may be interpreted as profit-taking, but investors remained confident in the company's performance.
• The upbeat forecast for UTHR, along with the higher price target from analysts, probably influenced the market's bullish trend today.

28.07.2024 - UTHR Stock was up 5.3%

• The positive market sentiment surrounding UTHR's product pipeline and potential for addressing medical needs likely drove the bullish movement in the stock.
• The recent sale of over $2.5 million in UTHR stock by the company's CEO may have sparked initial investor concerns, but it was likely viewed as a strategic decision rather than a reflection of UTHR's performance.
• The overall upbeat outlook in the biotechnology industry, as seen in a recent industry comparison, may have also influenced investors and contributed to UTHR's stock's bullish movement today.

26.01.2025 - UTHR Stock was down 8.1%

• Despite United Therapeutics surpassing Q4 earnings and revenue estimates, the stock experienced a bearish movement, indicating that the market may have had higher expectations.
• Investors might have been disappointed with the company's future guidance or outlook, leading to a sell-off of the stock.
• The market may have reacted negatively to key metrics that fell short of Wall Street projections, causing a decline in UTHR's stock price.

16.09.2024 - UTHR Stock was up 2.5%

• UTHR has shown remarkable performance in the market, boasting an impressive average annual return of 33.66% over the past 5 years.
• The stock's significant bullish movement today may be attributed to its continuous growth and the favorable market sentiment towards its innovative therapies.
• Investors are showing confidence in United Therapeutics' market position and growth potential, evident in its current market capitalization of $15.89 billion.

09.03.2025 - UTHR Stock was down 5.7%

• Despite the positive market sentiment and expectations of a strong performance in the upcoming period, UTHR faced significant bearish movement today.
• This unexpected downturn may be linked to investors taking profits, potentially motivated by the anticipation of positive earnings.
• Market dynamics or external factors could have also played a role in the stock's decline, counter to the optimistic outlook for UTHR's future earnings.

12.01.2025 - UTHR Stock was up 1.2%

• The positive movement in UTHR today could stem from favorable market sentiment towards the company's recent product advancements or financial performance.
• Comparisons made between UTHR and ZTS may have played a role in boosting investor trust in UTHR, potentially positioning UTHR as an appealing investment choice.
• Investors may have viewed UTHR as a more attractive stock in terms of value compared to ZTS, leading to increased buying interest and driving up the stock price.
• In summary, today's uptick in UTHR may be a result of internal company factors as well as evaluations against industry peers in the biotechnology field.

01.02.2024 - UTHR Stock was up 5.4%

• The bullish movement in UTHR stock today could be attributed to the positive earnings call transcript for Q4 2023, indicating strong financial performance and growth prospects for the company.
• The upgraded stock rating from "buy" to "strong-buy" by analysts may have also contributed to the bullish momentum, instilling confidence in investors regarding the future outlook of United Therapeutics.
• The focus on under-the-radar biotech stocks gearing up for potential liftoff could have generated increased interest and attention towards UTHR, positioning it as a promising investment opportunity within the biotech sector.

23.01.2024 - UTHR Stock was up 3.5%

• UTHR experienced a significant bullish movement.
• The upgrade to a "Strong-Buy" rating likely boosted investor confidence.
• Q4 earnings and sales exceeded expectations, attributed to robust Tyvaso sales.
• Record Q4 revenue and growth strategy highlighted by United Therapeutics strengthened investor optimism, driving the stock price surge.

24.04.2024 - UTHR Stock was down 1.5%

• Downgrading UTHR from a "strong-buy" to a "buy" rating may have caused uncertainty among investors, leading to a sell-off.
• The improved relative strength of competitors like Keros Therapeutics, Ascendis Pharma ADR, Arvinas, and TG Therapeutics might have shifted investor interest away from UTHR.
• The overall positive market sentiment towards other pharmaceutical companies with upgraded RS ratings could have contributed to the bearish movement in UTHR.
• Investors may be reallocating their portfolios based on the perceived market leadership of other pharmaceutical companies, impacting UTHR's stock performance negatively.

21.01.2024 - UTHR Stock was up 2.5%

• UTHR took legal action against the FDA, alleging that the FDA allowed Liquidia Corporation to deviate from established rules in the drug approval process. This action may have boosted investor confidence, leading to the bullish market movement.
• Despite a decrease in United Therapeutics shares following an earnings miss, the company achieved record annual revenue and significantly increased net income in 2023. This strong financial performance likely contributed to the positive market sentiment.
• The legal dispute with the FDA regarding Liquidia's drug expansion and the efforts to uphold fairness in the drug review process could have attracted investor interest, potentially fueling the bullish trend in UTHR's stock.

28.02.2024 - UTHR Stock was down 5.0%

• The bearish movement in UTHR stock today could be attributed to the CEO, Martine Rothblatt, selling a substantial amount of company shares, raising concerns among investors about the company's future prospects.
• Additionally, the announcement of a $1 billion stock buyback plan by United Therapeutics may have signaled to investors a lack of better investment opportunities within the company, leading to a negative sentiment.
• The broader market trend towards value-oriented stocks might have diverted attention and investment away from UTHR, impacting its stock price negatively.
• Overall, the combination of insider selling, buyback plan, and shifting investor preferences towards bargain stocks likely contributed to the bearish movement in United Therapeutics Corp's stock today.

30.03.2025 - UTHR Stock was up 2.1%

• UTHR's strong bullish movement today can be attributed to the company's impressive Q1 earnings and revenue results, surpassing analyst estimates by 5.41% and 9.39% respectively. This positive financial performance likely instilled confidence in investors, driving up the stock price.
• Despite the overall bullish market movement, it's interesting to note that there were downgrades from a top analyst, which could have initially caused some uncertainty. However, the market seemed to focus more on the robust earnings report, overshadowing the analyst's revised outlook.
• The market's reaction indicates that investors placed more weight on UTHR's solid financial fundamentals rather than the analyst's downgrade, showcasing the significance of strong earnings in influencing stock price movements.